PFE's oncology unit is in focus ahead of Q2 results, with key drugs facing both rising demand and market pressure.

ABBV's oncology sales might have dipped in Q2 as gains from newer drugs face pressure from Imbruvica's ongoing decline.

Boston conference will explore strategic partnering, device innovation, and delivery solutions for emerging therapeutics.

Fittingly enough, for its third acquisition in as many years, Deerfield Group has picked up Triple Threat Communications. | ...

The deal gives AstraZeneca’s rare disease unit Alexion access to specialized capsids developed by the Japanese biotech JCR ...

AstraZeneca’s rare disease unit Alexion has penned a $825 million deal for adeno-associated virus (AAV) capsids from existing ...

PFE's robust late-stage pipeline, recent FDA wins and deep oncology bets position it for long-term growth through 2030.

Executives who treat capital allocation as a CEO-level strategic discipline are best positioned to thrive in a volatile and increasingly capital-constrained environment.

U.S.-headquartered Alloy Therapeutics, a biotech firm focused on expanding access to drug discovery tools, said it has signed a memorandum of understanding with Serbia's state-owned operator of the ...

Shares in Summit Therapeutics have risen sharply on a report that AstraZeneca is in discussions for a partnership focused on ...

The PD-1xVEGF dealmaking wave that has captivated Western pharma companies is now surging within China. | Sino Biopharm said it will pay up to $951 million to acquire LaNova Medicines, which has ...

Antibiotic innovation, rising female UTI cases, and diagnostic advances are key drivers shaping the future of the UTI market. CA, UNITED STATES, July 15, 2025 /EINPresswire.com/ -- Urinary tract ...